Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | DRD1 | P21728 | 2/20 | 0.31 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | TK1 | P04183 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15196025 | 0.90 | HTT (0.36) | HTTLMNAALDH1A1GRIN1GRIN2B | |
| SCHEMBL3562767 | 0.82 | LMNA (0.34) | LMNAALDH1A1GRIN1GRIN2BDRD1 | |
| SCHEMBL3558259 | 0.81 | TK1 (0.35) | HTTDRD1TK1MET | |
| SCHEMBL3558541 | 0.79 | DRD1 (0.35) | HTTLMNAALDH1A1DRD1MET | |
| SCHEMBL3554398 | 0.79 | HTT (0.35) | HTTLMNAALDH1A1TK1MET | |
| SCHEMBL3567537 | 0.77 | TNKS (0.41) | HTTLMNATK1 | |
| SCHEMBL3567135 | 0.75 | TK2 (0.36) | HTTALDH1A1TYMPTK1 | |
| SCHEMBL3568177 | 0.75 | HTT (0.38) | HTTLMNAALDH1A1TYMPTK1 | |
| SCHEMBL5725218 | 0.74 | LMNA (0.52) | HTTLMNATK1 | |
| SCHEMBL3564722 | 0.74 | HTT (0.36) | HTTALDH1A1TK1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007750-B1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2013-08-21 | — | — | EP | disclosed |
| US-7727988-B2 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2010-06-01 | — | — | US | disclosed |
| US-7727988-B2 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2010-06-01 | — | — | US | disclosed |
| US-7727988-B2 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2010-06-01 | — | — | US | disclosed |
| EP-2007750-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | EP | disclosed |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| WO-2007113232-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113232-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | AZI2, NT5C3B, CYP1B1 | HTT 2295/4885LMNA 3803/4885ALDH1A1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.